<DOC>
	<DOCNO>NCT01235689</DOCNO>
	<brief_summary>Efficacy Safety two treatment model subject moderate severe Crohn 's Disease .</brief_summary>
	<brief_title>Efficacy Safety Two Treatment Models Subjects With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Diagnosis ileal , colonic ( include rectal ) , ileocolonic CD confirm use image technology endoscopy 6 year prior Baseline . CDAI score great equal 220 less equal 450 Baseline visit subject receive prednisone equivalent Baseline . CDAI score great equal 200 less equal 450 Baseline visit subject receive prednisone less equal 20 mg equivalent great equal 7 day Baseline . CDAI score great 150 less equal 450 Baseline visit subject receive prednisone great 20 mg equivalent great equal 7 day Baseline Subjects his/her legal representative voluntarily sign date informed consent approve compliant requirement study protocol approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) . Adequate cardiac , renal hepatic function determine Principal Investigator demonstrate Screening laboratory evaluation , questionnaire physical examination result indicate abnormal clinical condition would place subject undue risk thus preclude subject participation study . Subjects must able selfinject orally administer study medication designee Healthcare Professional assist Previous current biologic use Crohn 's disease participation biologic study Previous current use immunomodulators ( e.g. , methotrexate , azathioprine , 6mercaptopurine , JAK inhibitor , alphaintegrin ) Crohn 's disease participation Crohn 's disease study immunomodulator ( ) . Current use immunomodulators nonCrohn 's disease Baseline . Greater two previous course corticosteroid ( systemic corticosteroid ) budesonide ) Crohn 's Disease . A course define 1 ) total duration burst taper ≥ 4 week 2 ) prednisone equivalent ≥ 40 mg ( budesonide ≥ 9 mg ) least 2 week . Subjects poorly control medical condition : uncontrolled diabetes document history recurrent infection , unstable ischemic heart disease , moderate severe congestive heart failure ( NYHA class III IV ) , recent cerebrovascular accident condition , opinion Investigator sponsor , would put subject risk participation protocol Subjects positive C. difficile stool assay Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Efficacy Safety two treatment algorithms Subjects Moderate Severe Crohn 's Disease</keyword>
</DOC>